A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection
Public ClinicalTrials.gov record NCT06079320. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
AN INTERVENTIONAL PHASE 2/3, ADAPTIVE, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NON-HOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to learn about the safety and effects of sisunatovir. Sisunatovir is studied for the possible treatment of Respiratory Syncytial Virus (RSV). RSV is a virus that causes lung infections with cold-like symptoms, but it can cause severe illness in some people. Sisunatovir is studied in adults: * who are not admitted to the hospital and * who have high chances of having a severe illness from RSV infection. This study is seeking participants who: * Are confirmed to have RSV. * Have symptoms of a lung infection. * Are 18 years of age or older. * Have one or more of the following which increases the chances of RSV illness: * A long-term lung disease. * heart failure. * a condition that weakens the immune system. * Are 65 years of age or older and do not have any of the conditions above Half of the participants in this study will receive sisunatovir. The other half will receive a placebo for 5 days. Placebo looks same like the study medicine but does not have any medication. Both sisunatovir and placebo will be taken by mouth. The study will compare the experiences of people receiving sisunatovir to those of the people who do not. This will help decide if sisunatovir is safe and effective. Participants will attend about 8-10 study visits over 5 weeks. During this time, they will have: * visits at the study clinic, * blood work, * swabs of the nose, * questionnaires, * a follow-up phone call.
Study identification
- NCT ID
- NCT06079320
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 16 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 7, 2023
- Primary completion
- Sep 29, 2024
- Completion
- Sep 29, 2024
- Last update posted
- Nov 9, 2025
2023 – 2024
United States locations
- U.S. sites
- 14
- U.S. states
- 7
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| National Institute of Clinical Research | Garden Grove | California | 92844 | — |
| National Institute of Clinical Research | Westminster | California | 92683 | — |
| De La Cruz Research Center, LLC | Miami | Florida | 33184 | — |
| Adult Medicine of Lake County, Inc. | Mt. Dora | Florida | 32757 | — |
| Adult Medicine of Lake County | Mt. Dora | Florida | 32757 | — |
| Accellacare - DuPage | Oak Lawn | Illinois | 60453 | — |
| Mercury Street Medical Group, PLLC | Butte | Montana | 59701 | — |
| DM Clinical Research - AOM | Brooklyn | New York | 11220 | — |
| CHEAR Center LLC | The Bronx | New York | 10455 | — |
| Preferred Primary Care Physicians, Preferred Clinical Research (Ofc 18) | Pittsburgh | Pennsylvania | 15236 | — |
| Zenos Clinical Research | Dallas | Texas | 75230 | — |
| Biopharma Informatic, LLC | Houston | Texas | 77043 | — |
| Salma Mazhar, MD PA | Mesquite | Texas | 75149 | — |
| SMS Clinical Research | Mesquite | Texas | 75149 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06079320, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 9, 2025 · Synced Sep 13, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06079320 live on ClinicalTrials.gov.